Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
0 hedge funds and large institutions have $0 invested in Medicenna Therapeutics Corp. Common Shares in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $40.9K → $0 (-$40.9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$33.8K |
| 2 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
-$3.94K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$3.17K |
MDNA Hedge Fund Activity: Q1 2024 in Review
0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q1 2024, worth a combined $0 — down 100% from $40.9K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of MDNA and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Rathbones Group, exiting entirely with an estimated $33.8K sold.
- 0 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q1 2024, down from 3 in Q4 2023.
- Funds reported $0 of Medicenna Therapeutics Corp. Common Shares stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q1 2024 and 3 closed out, a net change of -3 holders.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q1 2024 was Rathbones Group, an estimated $33.8K sold.
Based on aggregated 13F filings for Q1 2024.